Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 23.99 |
|---|---|
| High | 25.40 |
| Low | 22.86 |
| Bid | 24.07 |
| Offer | 24.17 |
| Previous close | 24.21 |
| Average volume | 637.17k |
|---|---|
| Shares outstanding | 67.77m |
| Free float | 17.66m |
| P/E (TTM) | -- |
| Market cap | 1.64bn USD |
| EPS (TTM) | -1.14 USD |
Data delayed at least 15 minutes, as of Feb 10 2026 21:00 GMT.
More ▼
- Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium
- Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026
- Pulse Biosciences’ nPulse™ Cardiac Catheter to Be Featured in Multiple Presentations at the AF Symposium
- Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors
- Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium
- Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
- Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation
- Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse™ Technology
- Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
More ▼
